Orthofix International N.V. (OFIX) Shares Sold by Citadel Advisors LLC

Citadel Advisors LLC cut its stake in shares of Orthofix International N.V. (NASDAQ:OFIX) by 87.2% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 6,175 shares of the medical device company’s stock after selling 42,202 shares during the period. Citadel Advisors LLC’s holdings in Orthofix International N.V. were worth $287,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of OFIX. Nationwide Fund Advisors raised its position in Orthofix International N.V. by 94.7% during the first quarter. Nationwide Fund Advisors now owns 24,441 shares of the medical device company’s stock worth $932,000 after acquiring an additional 11,888 shares during the period. Bank of New York Mellon Corp raised its position in Orthofix International N.V. by 122.5% during the first quarter. Bank of New York Mellon Corp now owns 242,068 shares of the medical device company’s stock worth $9,236,000 after acquiring an additional 133,281 shares during the period. BNP Paribas Arbitrage SA raised its position in Orthofix International N.V. by 68.9% during the first quarter. BNP Paribas Arbitrage SA now owns 4,656 shares of the medical device company’s stock worth $178,000 after acquiring an additional 1,900 shares during the period. Comerica Bank acquired a new position in Orthofix International N.V. during the first quarter worth $783,000. Finally, UBS Asset Management Americas Inc. acquired a new position in Orthofix International N.V. during the first quarter worth $229,000. Institutional investors own 94.40% of the company’s stock.

A number of equities analysts have weighed in on OFIX shares. Ladenburg Thalmann Financial Services started coverage on shares of Orthofix International N.V. in a research report on Wednesday, June 14th. They set a “buy” rating and a $53.25 price objective for the company. Langenberg & Company reiterated a “buy” rating and issued a $53.25 target price on shares of Orthofix International N.V. in a research report on Wednesday, June 14th. BTIG Research initiated coverage on shares of Orthofix International N.V. in a research report on Wednesday, June 21st. They issued a “buy” rating and a $52.00 target price for the company. Zacks Investment Research upgraded shares of Orthofix International N.V. from a “sell” rating to a “hold” rating in a research report on Thursday, July 6th. Finally, BidaskClub cut shares of Orthofix International N.V. from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Orthofix International N.V. presently has an average rating of “Buy” and an average target price of $52.75.

Shares of Orthofix International N.V. (OFIX) opened at 49.08 on Thursday. The company’s 50-day moving average is $48.74 and its 200 day moving average is $44.40. The firm has a market capitalization of $891.78 million, a PE ratio of 114.94 and a beta of 0.20. Orthofix International N.V. has a 52-week low of $32.51 and a 52-week high of $51.09.

Orthofix International N.V. (NASDAQ:OFIX) last announced its earnings results on Monday, August 7th. The medical device company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.01. Orthofix International N.V. had a net margin of 1.88% and a return on equity of 9.96%. The firm had revenue of $108.90 million during the quarter, compared to the consensus estimate of $102.94 million. During the same quarter in the previous year, the company posted $0.41 EPS. The firm’s revenue for the quarter was up 4.6% on a year-over-year basis. Equities analysts expect that Orthofix International N.V. will post $1.56 earnings per share for the current fiscal year.

In other news, CEO Brad Mason sold 2,733 shares of the company’s stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $48.10, for a total transaction of $131,457.30. Following the completion of the transaction, the chief executive officer now owns 188,053 shares of the company’s stock, valued at approximately $9,045,349.30. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Raymond Fujikawa sold 6,364 shares of the company’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $47.06, for a total transaction of $299,489.84. Following the transaction, the insider now directly owns 31,084 shares of the company’s stock, valued at approximately $1,462,813.04. The disclosure for this sale can be found here. Insiders sold a total of 23,406 shares of company stock valued at $1,138,531 in the last three months. 5.60% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.com-unik.info/2017/10/12/orthofix-international-n-v-ofix-shares-sold-by-citadel-advisors-llc.html.

Orthofix International N.V. Profile

Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.

Institutional Ownership by Quarter for Orthofix International N.V. (NASDAQ:OFIX)

What are top analysts saying about Orthofix International N.V.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Orthofix International N.V. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit